Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02637245 · ClinicalTrials.gov registry record

Imaging Parameters and DME Treatment Response

A clinical trial, sponsored by Duke University.

Completed
Registry status
32
Enrollment target

NCT02637245 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02637245 has completed, sponsored by Duke University.

COMPLETED
Registry status
32 participants
Enrollment target

Study Summary

Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. While anti-VEGF treatments and to a lesser extent corticosteroid and macular photocoagulation have improved outcomes in patients with DME, no single therapy is universally effective and currently there is no a priori means of determine which patients will respond best to any given therapy. The purpose of this study is to determine whether specific parameters of ocular imaging studies including optical coherence tomography and fluorescein angiography can predict response to treatment in patients with DME. This is a prospective observational cohort study that will collect clinical data and imaging studies obtained as standard of care. Up to 150 subjects with clinically significant DME will be enrolled at Duke Eye Center or its satellite offices. These imaging studies will be analyzed to determine whether specific parameters are associated with poor or favorable response to specific treatments. There will be no intervention as part of this observational trial, thus the primary risk to subjects is loss of confidentiality, which will be minimized by the study team.

Interventions

  • OTHER No intervention

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2015-05
Est. Completion 2017-12

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02637245

The ClinicalTrials.gov registry entry for NCT02637245 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.

NCT02637245 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02637245 about?

NCT02637245 is a clinical study titled "Imaging Parameters and DME Treatment Response". Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. While anti-VEGF treatments and to a lesser extent corticosteroid and macular photocoagulation have improved outcomes in patients with DME, no single therapy is universally effective and currently there is no a...

What is the current status of trial NCT02637245?

This trial is currently completed. The enrollment target is 32 participants. The study started on 2015-05. Estimated completion is 2017-12.

What interventions are being tested in trial NCT02637245?

The interventions under investigation include: No intervention (OTHER).

Who is sponsoring clinical trial NCT02637245?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.